| 摘要 |
Compounds of formula (I), wherein R<1> and R<2> each independently represent: hydrogen, C1-8alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-4alkyl, arylC1-4alkyl, C2-6hydroxyalkyl or R<3>R<4>NC2-6alkyl (where R<3> and R<4> independently represent H or C1-4alkyl) or NR<1>R<2> represents a saturated heterocyclic ring containing 4 to 9 ring members, one of which may optionally be a further heteroatom selected from O, S or NR<5>, (where R<5> is H, C1-4alkyl or arylC1-4alkyl), which ring may optionally be substituted by one or two substituents selected from C1-6alkyl and C1-6alkoxy; X represents O, S or NR<6> (where R<6> is hydrogen, C1-4alkyl or arylC1-4alkyl); Y represents O, S, C=O or a bond; n is 2 to 5; m is 1 to 5 (providing that when m is 1, Y represents a bond); and Ar represents phenyl optionally substituted by 1-3 substituents selected from halo, C1-8alkyl, C1-8alkoxy, C1-2alkylenedioxy e.g. methylenedioxy, trifluoromethyl, trifluoromethyloxy, or by a group Ph(Alk<1>)pA(Alk<2>)q- where Ph isoptionally substituted phenyl, A is a bond, O, S, -C=O or CH=CH, Alk<1> and Alk<2> independently represent C1-4alkyl which may be straight or branched and p and q are independently 0 or 1, provided that the length of -(Alk<1>)pA(Alk<2>)q- does not exceed 5 atoms, or Ar is an optionally substitued tricyclic heteroaryl group (a) in which Y<1> is Y<2>(CH2)r where r is 0 or 1 and Y<2> is O, S or NR<7> where R<7> is hydrogen or C1-4alkyl, Z is (CH2)s or -CH=CH-, s is 0, 1 or 2 or Ar is the corresponding tricyclic dehydro ring system; and pharmaceutically acceptable salts thereof are useful as atherapeutic agents, e.g. for the treatment of ischaemic stroke. |
